Enhanced survival with implantable scaffolds that capture metastatic breast cancer cells in vivo

Cancer Research

Volumn 76, Issue 18, 2016, Pages 5209-5218

  Rao, Shreyas S ^a   Bushnell, Grace G ^b   Azarin, Samira M ^c   Spicer, Graham ^d   Aguado, Brian A ^e   Stoehr, Jenna R ^f   Jiang, Eric J ^d   Backman, Vadim ^d   Shea, Lonnie D ^b   Jeruss, Jacqueline S ^b  

^a University of Alabama   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c University of Minnesota   (United States)

^d Northwestern University   (United States)

^e University of Colorado at Boulder   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; MOLECULAR SCAFFOLD; POLYCAPROLACTONE; POLYESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; EARLY DIAGNOSIS; FEMALE; FOREIGN BODY REACTION; IMMUNE RESPONSE; IMPLANT; IN VIVO STUDY; METASTATIC BREAST CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; DISEASE MODEL; FLOW CYTOMETRY; METASTASIS; NONOBESE DIABETIC MOUSE; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; SCID MOUSE; TISSUE SCAFFOLD;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; POLYESTERS; TISSUE SCAFFOLDS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84988919766     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2106     Document Type: Article

References (50)

1. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
2. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
3. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
4. Murakami R, Kumita S, Yoshida T, Ishihara K, Kiriyama T, Hakozaki K, et al. FDG-PET/CT in the diagnosis of recurrent breast cancer. Acta Radiol 2012;53:12-6.
5. Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 2004;14:99-105.
6. Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004;233:139-48.
7. Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 2010;20:96-9.
8. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011;192:373-82.
9. Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells. Cancer Res 2013;73:8-11.
10. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007;253:180-204.
11. Azarin SM, Yi J, Gower RM, Aguado BA, Sullivan ME, Goodman AG, et al. In vivo capture and label-free detection of early metastatic cells. Nat Commun 2015;6:8094.
12. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
13. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 2006;66:11089-93.
14. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009;9:285-93.
15. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011;21:139-46.
16. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;133:571-3.
17. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
18. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev 2006;25:521-9.
19. Jang JH, Rives CB, Shea LD. Plasmid delivery in vivo from porous tissue-engineering scaffolds: transgene expression and cellular transfection. Mol Ther 2005;12:475-83.
20. Yi J, Backman V. Imaging a full set of optical scattering properties of biological tissue by inverse spectroscopic optical coherence tomography. Opt Lett 2012;37:4443-5.
21. Yi J, Radosevich AJ, Rogers JD, Norris SCP, Capoglu IR, Taflove A, et al. Can OCT be sensitive to nanoscale structural alterations in biological tissue? Opt Express 2013;21:9043-59.
22. Yi J, Radosevich AJ, Stypula-Cyrus Y, Mutyal NN, Azarin SM, Horcher E, et al. Spatially resolved optical and ultrastructural properties of colorectal and pancreatic field carcinogenesis observed by inverse spectroscopic optical coherence tomography. J Biomed Opt 2014;19:36013.
23. Milsom CC, Lee CR, Hackl C, Man S, Kerbel RS. Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rgamma (null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis. PLoS One 2013;8:e71270.
24. Guerin E, Man S, Xu P, Kerbel RS. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res 2013;73:2743-8.
25. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015;15:73-86.
26. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006;8:1369-75.
27. Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM, et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 2012;72:3906-11.
28. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
29. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009;15:35-44.
30. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009;4:e6562.
31. Radosevich AJ, Mutyal NN, Yi J, Stypula-Cyrus Y, Rogers JD, Goldberg MJ, et al. Ultrastructural alterations in field carcinogenesis measured by enhanced backscattering spectroscopy. J Biomed Opt 2013;18:097002.
32. Radosevich AJ, Mutyal NN, Rogers JD, Gould B, Hensing TA, Ray D, et al. Buccal spectral markers for lung cancer risk stratification. PLoS One 2014;9:e110157.
33. Moreau JE, Anderson K, Mauney JR, Nguyen T, Kaplan DL, Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res 2007;67:10304-8.
34. Holzapfel BM, Wagner F, Loessner D, Holzapfel NP, Thibaudeau L, Crawford R, et al. Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials 2014;35:4108-15.
35. Seib FP, Berry JE, Shiozawa Y, Taichman RS, Kaplan DL. Tissue engineering a surrogate niche for metastatic cancer cells. Biomaterials 2015;51:313-9.
36. Lee J, Li M, Milwid J, Dunham J, Vinegoni C, Gorbatov R, et al. Implantable microenvironments to attract hematopoietic stem/cancer cells. Proc Natl Acad Sci U S A 2012;109:19638-43.
37. Bersani F, Lee J, Yu M, Morris R, Desai R, Ramaswamy S, et al. Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models. Cancer Res 2014;74:7229-38.
38. Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE3rd. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 2013;140:13-21.
39. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009;183:937-44.
40. Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, et al. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010;40:3347-57.
41. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009;50:799-807.
42. Srivastava MK, Zhu L, Harris-White M, Kar U, Huang M, Johnson MF, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012;7:e40677.
43. Li Z, Pang Y, Gara SK, Achyut B, Heger C, Goldsmith PK, et al. Gr1+CD11b+ cells are responsible for tumor promoting effect of TGFβ in breast cancer progression. Int J Cancer 2012;131:2584-95.
44. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α;. Cancer Res 2013;73:6413-23.
45. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58:49-59.
46. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.
47. Cole S, Montero A, Garret-Mayer E, Onicescu G, Vandenberg T, Hutchens S, et al. Elevated Circulating Myeloid Derived Suppressor Cells (MDSC) Are Associated with Inferior Overall Survival (OS) and Correlate with Circulating Tumor Cells (CTC) in Patients with Metastatic Breast Cancer. In: Thirty-Second Annual CTRCAACR San Antonio Breast Cancer Symposium: Cancer Research, San Antonio, TX2009.
48. Couet F, Rajan N, Mantovani D. Macromolecular biomaterials for scaffold-based vascular tissue engineering. Macromol Biosci 2007;7:701-18.
49. Sung HJ, Meredith C, Johnson C, Galis ZS. The effect of scaffold degradation rate on three-dimensional cell growth and angiogenesis. Biomaterials 2004;25:5735-42.
50. Kohn J, Abramson S, Langer R. Bioresorbable and Bioerodible Materials, In: Ratner BD, Hoffman AS, Schoen FJ, andLemons JE, editors. Biomaterials Science: An Introduction to Materials in Medicine. San Diego: Elsevier Academic Press; 2004. p.115-27.